💊 İlaçlar A-Z 🧬 Hedefler 🛠 Araçlar 📚 Rehberler
Tüm İlaçlar İlaç Sınıfları Terapötik Alanlar Yan Etkiler
Rehberler Sözlük Zaman Çizelgesi
Karşılaştırmalar İlaç Yolculukları İlaç Aileleri
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Mefenamic Acid

CHEMBL686 Phase 4 Onaylandı Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
241.3 g/mol
LogP
5.1
Phase
4

An NSAID used for short-term treatment of mild-to-moderate pain and menstrual cramps by blocking prostaglandin synthesis, and is also being studied for its effects in inflammatory conditions. It is typically used for no more than seven days at a time.

Moleküler Ağırlık

241,2800 g/mol

LogP

5,10

TPSA

49,30 Ų

Lipinski RO5

Geçer

Terapötik Alanlar

Pain Management Chronic Pain

Etki Mekanizması

Inhibits cyclooxygenase (COX-1 and/or COX-2) enzymes, reducing the synthesis of prostaglandins and thromboxanes from arachidonic acid. This produces anti-inflammatory, analgesic, and antipyretic effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanizma

Inhibits cyclooxygenase (COX-1 and/or COX-2) enzymes, reducing the synthesis of prostaglandins and thromboxanes from arachidonic acid. This produces anti-inflammatory, analgesic, and antipyretic effects.

2D Yapı

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
Cc1cccc(Nc2ccccc2C(=O)O)c1C

                

                

                
                

                    
InChI

                    
InChI=1S/C15H15NO2/c1-10-6-5-9-13(11(10)2)16-14-8-4-3-7-12(14)15(17)18/h3-9,16H,1-2H3,(H,17,18)

                

                

                

                    
                    

                        
Molecular Formula

                        
C15H15NO2

                    

                    
                    

                        
HBD / HBA

                        
2 / 3

                    

                    
                    

                        
Döndürülebilir Bağlar

                        
3

                    

                    
                    
                    

                        
Ağır Atomlar

                        
18

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Sıkça Sorulan Sorular

                

                    
                    

                        
                        

                            
An NSAID used for short-term treatment of mild-to-moderate pain and menstrual cramps by blocking prostaglandin synthesis, and is also being studied for its effects in inflammatory conditions. It is typically used for no more than seven days at a time.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Inhibits cyclooxygenase (COX-1 and/or COX-2) enzymes, reducing the synthesis of prostaglandins and thromboxanes from arachidonic acid. This produces anti-inflammatory, analgesic, and antipyretic effects.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Mefenamic Acid is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL686.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 4044.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
Tıbbi Sorumluluk Reddi

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.